https://assets.capyfin.com/instruments/678fdc13234e27009c5d57fc.png avatar
McKesson
🇺🇸 NYSE:MCK
View Company
OverviewEarningsDividends
•
Mar 31, 2024

McKesson Q4 2024 Earnings Report

McKesson's Q4 2024 earnings decreased by 14% due to a higher tax rate, partially offset by a lower share count, and growth in the U.S. Pharmaceutical segment.

Key Takeaways

McKesson Corporation reported an 11% increase in fourth-quarter revenues, reaching $76.4 billion. However, adjusted earnings per diluted share decreased by 14% to $6.18, driven by a higher tax rate, partially offset by a lower share count and growth in the U.S. Pharmaceutical segment.

Consolidated revenues increased by 11% to $76.4 billion.

Earnings per diluted share from continuing operations increased by $0.31 to $6.02.

Adjusted Earnings per Diluted Share decreased by 14% to $6.18.

Growth in revenue was primarily driven by the U.S. Pharmaceutical segment.

Total Revenue
$76.4B
Previous year: $68.9B
+10.8%
EPS
$6.18
Previous year: $7.19
-14.0%
Dividends per Share
$0.62
U.S. Pharma Op. Profit
$1.06B
U.S. Pharma Adj. Profit
$901M
Gross Profit
$3.59B
Previous year: $3.07B
+16.9%
Cash and Equivalents
$4.58B
Previous year: $4.68B
-2.0%
Free Cash Flow
$3.6B
Previous year: $4.6B
-21.8%
Total Assets
$67.4B
Previous year: $62.3B
+8.2%

McKesson

McKesson

McKesson Revenue by Segment

McKesson Revenue by Geographic Location

Forward Guidance

McKesson anticipates Fiscal 2025 Adjusted Earnings per Diluted Share of $31.25 to $32.05 reflecting continued operating momentum, a strong financial position, and a balanced approach to capital deployment.

Positive Outlook

  • Continued operating momentum
  • Strong financial position
  • Balanced approach to capital deployment
  • Focus on company priorities
  • Leveraging assets and capabilities to drive sustainable growth

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View McKesson